PF-06763809 / Pfizer - LARVOL DELTA

A phase I, randomized, double-blind study to assess the safety, tolerability, and efficacy of the topical RORC2 inverse agonist PF-06763809 in participants with mild-to-moderate plaque psoriasis. (PubMed, Clin Exp Dermatol) - P1 | "Using a psoriasis plaque test design, PF-06763809 was well tolerated with an acceptable safety profile in participants with psoriasis, but without reduction in skin infiltrate thickness or disease biomarkers."

Clinical • Journal • Dermatology • Dermatopathology • Immunology • Psoriasis • IL17A

Termination of Karo agreement with Pfizer (PRNewswire.co.uk) - "Karo Pharma AB...has been informed by Pfizer Inc....about its decision to terminate the Research Collaboration and License Agreement, which the two companies entered in December 2011. Following the wind-down of this agreement, there will be no active collaboration agreements between the two companies. This information follows Pfizer's decision to terminate a specific development project, PF-06763809, which Karo informed about in press releases issued on November 5th and November 20th, 2019."

Licensing / partnership

Further clarification regarding the ROR-gamma project (Yahoo Finance) - "The development project, PF-06763809, was run internally by Pfizer....There has been no involvement from Karo Pharma in the project nor the decision to terminate was made by Pfizer at Pfizer's sole discretion....Karo Pharma communicated theoretical milestones of up to 200 MUSD related to the Pfizer agreement. These potential milestone payments were all related to the specific project, PF-06763809. Given the termination of PF-06763809, none of these milestone payments will materialize."

Clinical • Discontinued

Termination of project regarding ROR-gamma (PRNewswire) - "In December 2011, Karo Pharma Aktiebolag ('Karo Pharma') entered into a research collaboration and license agreement with Pfizer, with the purpose of discovering and developing substances that hamper the activity in the nuclear hormone receptor ROR-gamma, for treatment of autoimmune diseases....Pfizer has informed Karo Pharma about its decision to terminate the specific development project, PF-06763809. As a result, Karo Pharma will not receive further development and sales milestones related to the project."

Discontinued

Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis (clinicaltrials.gov) - P1; N=18; Completed; Sponsor: Pfizer; Active, not recruiting ➔ Completed

Clinical • Trial completion

Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis (clinicaltrials.gov) - P1; N=18; Active, not recruiting; Sponsor: Pfizer; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed